Industry Briefs: September 17, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: September 17, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Almac has launched a new histone reagents catalog and custom synthesis service. Read More

The biopharmaceutical company Bionomics has acquired Eclipse Therapeutics, a stem-cell research company. Read More

Catalent Pharma Solutions and CTC Bio have agreed to provide services to South Korean pharmaceutical companies seeking to commercialize solid oral-dose and controlled-release products in the US and Europe. Read More

Haupt Pharma successfully passed inspections by FDA at four sites in Germany during the first half of 2012. Read More

Recipharm has received regulatory approval from the French health authorities to fill biotechnology products at its site in Monts, France. Read More

Sanofi’s subsidiary Genzyme has received FDA approval for a new molecular entity, Aubagio (teriflunomide), a once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis. Read More

SGS Life Science Services completed an expansion of its Fairfield, New Jersey, facility on Sept. 20, 2012. The expansion enlarges the size of the facility from 15,000 to 30,000 ft2 by adding modernized and new GMP/GLP-compliant laboratories, and increases ICH Zone 1–4 storage capacities.

West has launched B.safe, its syringe-safety system technology system. Read More

People Notes

Emisphere Technologies has appointed Alan L. Rubino as president and CEO, effective immediately. Read More

Patheon has appointed Harry Gill to senior vice-president of quality and continuous improvement. Read More

Unicep, contract packaging company, has announced new ownership with Marcus Anderson, current president, and Clint Marshall, current chief financial officer purchasing the company from its founder, John Snedden. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here